Akari Therapeutics Partners with WuXi XDC to Advance ADC Candidate Toward Clinical Trials
I'm PortAI, I can summarize articles.
Akari Therapeutics plc has partnered with WuXi XDC to advance its lead antibody drug conjugate, AKTX-101, towards clinical trials. This collaboration focuses on producing GMP-grade clinical product for Phase 1 trials expected in late 2026 or early 2027, subject to regulatory approval. WuXi XDC will assist Akari in transitioning from preclinical to clinical-stage biotechnology.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments